Edg receptor agonists

A compound represented by Formula I:

• or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• Ar is phenyl or naphthyl;
• m=0 or 1;
• n=0 or 1;
• A is selected from the group consisting of:
• —CO2H, —PO3H2, —PO2H, —SO3H, —PO(C1-3alkyl)OH and 1H-tetrazol-5-yl;
• R1 and R2 are each independently selected from the group consisting of:
• hydrogen, halo, hydroxy, —CO2H and C1-4alkyl, optionally substituted from one up to the maximum number of substitutable positions with halo;
• R3 is selected from the group consisting of:
• hydrogen and C1-4alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:
• halo and hydroxy;
• each R4 is independently selected from the group consisting of:
• halo, C1-4alkyl and C1-3alkoxy, said C1-4alkyl and C1-3alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,
• C is selected from the group consisting of:
• (1) C1-8alkyl, C1-8alkoxy, —(C═O)—C1-6alkyl or —CHOH—C1-6alkyl, said C1-8alkyl, C1-8alkoxy, —(C═O)—C1-6alkyl and —CHOH—C1-6alkyl optionally substituted with phenyl, and
• (2) phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of:
• halo, phenyl, C1-4alkyl and C1-4alkoxy, said C1-4alkyl and C1-4alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of:
• halo and C1-4alkyl, optionally substituted with 1-3 halo groups,
• or C is not present;
• when C is not present then B is selected from the group consisting of:
• phenyl, C5-16alkyl, C5-16alkenyl, C5-16alkynyl, —CHOH—C4-15alkyl, —CHOH—C4-15alkenyl, —CHOH—C4-15alkynyl, C4-15alkoxy, —O—C4-15alkenyl, —O—C4-15alkynyl, C4-15alkylthio, —S—C4-15alkenyl, —S—C4-15alkynyl, —CH2—C3-14alkoxy, —CH2—O—C3-14alkenyl, —CH2—O—C3-14alkynyl, —(C═O)—C4-15alkyl, —(C═O)—C4-15alkenyl, —(C═O)—C4-15alkynyl, —(C═O)—O—C3-14alkyl, —(C═O)—O—C3-14alkenyl, —(C═O)—N(R6)(R7)—C3-14alkyl, —(C═O)—N(R6)(R7)—C3-14alkenyl, —(C═O)—N(R6)(R7)—C3-14alkynyl, —N(R6)(R7)—(C═O)—C3-14alkyl, —N(R6)(R7)—(C═O)—C3-14alkenyl and —N(R6)(R7)—(C═O)—C3-14alkynyl,
• when C is phenyl or HET then B is selected from the group consisting of:
• C1-6alkyl, C1-5alkoxy, —(C═O)—C1-5alkyl, —(C═O)—O—C1-4alkyl, —(C═O)—N(R6)(R7)—C1-4alkyl,
• phenyl and HET, and
• when C is C1-8alkyl, C1-8alkoxy, —(C═O)—C1-6alkyl or —CHOH—C1-6alkyl then B is phenyl;
• and
• R6 and R7 are independently selected from the group consisting of:
• hydrogen, C1-9alkyl and —(CH2)p-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of:
• C1-3alkyl and C1-3alkoxy, each optionally substituted with 1-3 halo groups.